ArticleAnalytical and bioanalytical chemistry2026
Biomarker discovery for lung adenocarcinoma diagnosis using liquid chromatography-mass spectrometry-based enhanced pseudotargeted metabolomics.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma, the most prevalent subtype of non-small cell lung cancer, is often diagnosed at advanced stages due to the lack of effective early screening methods, leading to poor patient outcomes. In this study, an enhanced pseudotargeted metabolomics approach was developed using liquid chromatography-mass spectrometry, combining untargeted-level coverage with targeted quantitative accuracy while enabling simplified clinical implementation. Serum samples from early-stage lung adenocarcinoma (LUAD) patients and healthy controls were analyzed using this method to identify potential biomarkers and establish a diagnostic model for early LUAD detection. A total of 329 serum samples were divided into discovery, internal validation, and external validation cohorts. Through non-parametric tests and machine learning algorithms, 113 differential metabolites were identified. Glycerophosphocholine and glutamine were validated as potential biomarkers for early LUAD diagnosis; the diagnostic model based on these biomarkers demonstrated good discriminative power, with AUCs of 0.972 and 0.867 in the internal and external validations, respectively. Additionally, comparative analysis between stage I and stage II patients revealed significant metabolic changes including elevated levels of choline, and sphingosine, and decreased levels of 3-dehydroteasterone and PC 31:0. These findings provided new insights into the metabolic alterations associated with LUAD progression and highlighted the potential of pseudotargeted metabolomics in discovering the metabolite biomarkers for early diagnosis of LUAD.
Indexed as
Identifiers
40938415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.